Quantifying the Magnitude and Cost of Collecting Extraneous Protocol Data

American Journal of Therapeutics

Volumn 22, Issue 2, 2015, Pages 117-124

  Getz, Kenneth A ^a   Stergiopoulos, Stella ^a   Marlborough, Michelle ^b   Whitehill, Jane ^c   Curran, Marla ^d   Kaitin, Kenneth I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Medidata Solutions Worldwide   (United States)

^c REGENERON PHARMACEUTICALS INC   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

clinical data; excessive clinical data; extraneous clinical data; protocol complexity; protocol design

Indexed keywords

ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL (TOPIC); COST; DATA COLLECTION METHOD; DRUG INDUSTRY; HUMAN; NONCORE PROCEDURE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; ECONOMICS; INFORMATION PROCESSING; METHODOLOGY; PROCEDURES;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DATA COLLECTION; DRUG INDUSTRY; HUMANS; RESEARCH DESIGN;

EID: 84925268004     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31826fc4aa     Document Type: Article

References (11)

1. Getz K, Campo R, Kaitin K. Variability in protocol design complexity by phase and therapeutic area. Drug Inform J. 2011;45:413-420.
2. Getz K, Wenger J, Campo R, et al. Assessing the impact of protocol design change on clinical trial performance. Am J Ther. 2008;15:449-456.
3. DiMasi Joseph A, Grabowski Henry G. R&D costs and returns to new drug development: a review of the evidence. In: Danzon PM, Nicholson S, eds. The Oxford Handbook of The Economics of the Biopharmaceutical Industry. Oxford, United Kingdom: Oxford University Press; 2012:21-46.
4. Getz K, Zuckerman R, Cropp A, et al. Measuring the incidence, causes, and repercussions of protocol amendments. Drug Info J. 2011;45:265-275.
5. Friedman L, Furberg C, DeMets D. Data Collection and Quality Control in the Fundamentals of Clinical Trials. Springer Science and Business Media; 2010:199-214.
6. Nahm ML, Pieper CF, Cunningham MM. Quantifying data quality for clinical trials using electronic data capture. PLoS One. 2008;3:e3049. doi:10.1371/journal.pone.0003049.
7. Abrams J, Erwin R, Fyfe G, et al. Data submission standards and evidence requirements. Presented at: The Conference on Clinical Cancer Research, Panel 1. Washington, DC: Engelberg Center for Health Care Reform; 2009.
8. Clark T. Data is king. International clinical trials. Samedan LTD Pharmaceutical Publishers. 2012;173:32-42.
9. Ross S, Grant A, Counsell C, et al. Barriers to participation in randomized controlled trials - a systematic review. J Clin Epidemiol. 1999;52:1143-1156.
10. Madsen S, Holm S, Riis P. Ethical aspects of clinical trials. Attitudes of public and out-patients. J Intern Med. 1999; 245:571-579.
11. Mathieu M, ed. Parexel Biopharmaceutical R&D Statistical Sourcebook 2011/2012. Boston, MA: Parexel Inernational Corporation; 2011:83.